iCAD Expands Executive Sales Leadership Team as Business Grows
18 déc. 2023 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Dec. 18, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced the expansion of its sales...
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
28 nov. 2023 08h00 HE
|
iCAD, Inc.
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow and support clinicians in delivering more personalized...
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
27 nov. 2023 08h00 HE
|
iCAD, Inc.
New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman’s one to two-year risk for breast...
iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution
20 nov. 2023 08h00 HE
|
iCAD, Inc.
Offering radiology the most complete breast health solution, including breast density assessment, breast cancer detection, and thorough risk evaluation, including lifetime, genetic, and short-term 1-...
iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
14 nov. 2023 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast...
iCAD Reports Financial Results for Third Quarter Ended September 30, 2023
13 nov. 2023 16h01 HE
|
iCAD, Inc.
NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast...
iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023
30 oct. 2023 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast...
iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta
23 oct. 2023 08h01 HE
|
iCAD, Inc.
NASHUA, N.H., Oct. 23, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions announced today that Elekta...
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
16 août 2023 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health...
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
14 août 2023 16h01 HE
|
iCAD, Inc.
NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its...